Muenster

• A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have heart disease due to TTR amy … Ended
  2023-506824-96-00 4 2023-05-23 The present study will include a population of patients with establish
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy
• A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in … Ended
  2023-510047-37-00 4 2023-03-30 Treatment-resistant depression (TRD)
• A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute … Ended
  2024-513706-56-00 4 2023-03-22 Acute-on-chronic liver failure (ACLF) is characterized by hepatic and
• An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended
  2022-501850-12-00 4 2023-03-15 Psoriasis
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• Moisturiser effect on atopic dermatitis relapse prevention in children Ended
  2022-501184-41-00 6 2023-02-13 atopic dermatitis/eczema
• A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended
  2023-506931-13-00 5 2023-01-30 Overweight and obesity and type 2 diabetes
• A trial to compare efficacy and safety of follitropin delta versus placebo (inactive treatment) in the treatment of men with idiopathic infe … Ended
  2023-508430-34-00 4 2023-01-12 Idiopathic male infertility (including oligoasthenozoospermia).
• Phase 2b Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Ended
  2024-514975-16-00 4 2022-12-22 Non-infectious, Intermediate-, Posterior- or Pan-uveitis
• Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia. Ended
  2024-517377-24-00 3 2022-12-20 Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic s
• Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy … Ended
  2024-512621-88-00 4 2022-12-06 Acute Respiratory Distress Syndrome
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy Ended
  2023-509876-40-00 4 2022-11-22 Multiple System Atrophy
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch … Ended
  2024-516988-87-00 4 2022-11-09 Chronic Inducible Urticaria
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 BRCA Mutations and Early Stage HER2-Negative Breast Cancer
• Zibotentan and Dapagliflozin combination, Evaluated in Liver cirrhosis (ZEAL study) Ended
  2023-505405-17-00 4 2022-10-07 Liver cirrhosis with features of portal hypertension.
• MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended
  2023-503615-14-00 4 2022-09-29 Relapsed or Refractory Classical Hodgkin Lymphoma
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s D … Ended
  2023-509835-26-00 4 2022-07-06 Huntington’s Disease
• Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight … Ended
  2023-509668-11-00 6 2022-06-15 Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.

Showing 529–552 of 604 trials